ROCKVILLE, Md. ROCKVILLE, Md. GlycoMimetics Inc. on Friday reported a loss of $9.2 million in its third quarter. The Rockville, Maryland-based company said it had a loss of 14 cents.
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory Acute Myeloid Leukemia on track to be reported by end of Q2 2024
NDA filing for uproleselan anticipated by end.
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET.
To access the call.
Short Interest in GlycoMimetics, Inc. (NASDAQ:GLYC) Declines By 7.8% kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.